Expert Review of Clinical Immunology

Papers
(The H4-Index of Expert Review of Clinical Immunology is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Natural history of COVID-19 and therapeutic options98
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis91
Circulating Calprotectin as a Biomarker of COVID-19 Severity76
A comparative review of immunoassays for COVID-19 detection76
The role of IL-6 and IL-6 blockade in COVID-1969
Breast implant illness: scientific evidence of its existence63
SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives58
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives43
An update on VEXAS syndrome42
Epidemiology of rheumatoid arthritis: genetic and environmental influences41
The infection risks of JAK inhibition40
The emerging role of type 2 inflammation in asthma35
The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review35
Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion35
Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis30
Generalized pustular psoriasis: current management status and unmet medical needs in Japan28
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults28
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection28
Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus27
Mechanical ventilation in Guillain–Barré syndrome25
Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation25
Emerging therapies for ulcerative colitis24
JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials24
Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events24
Emerging therapy options for IgG4-related disease24
0.079241037368774